Here’s why Ozempic maker’s new weight-loss drug isn’t good enough for investors

New trial data showed CagriSema led to “superior” weight loss, but at a rate much less than original expectations of 25%.

Topics

Novo Nordisk shares fall 6.3% after latest trial results for its next-generation weight loss drug

Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its CagriSema weight-loss drug.
CNBC - 5h
Chipmakers are finding that good earnings aren't enough to please Wall Street

After investors poured into semiconductor stocks last year, expectations are high, and companies are having trouble making Wall Street happy.
CNBC - 3d
These accounts can be the 'worst possible asset’ for retirement, expert says. Here's why

Many investors don't plan for future taxes when contributing to traditional IRAs. Here are the key things to know.
CNBC - 2d
Weight Loss Drug Will Be Offered for $499 a Month for Some Patients

Some commercially insured patients stand to save $150 per month on Wegovy, a popular obesity medication. Patients on Medicare and Medicaid are not eligible.
The New York Times - 4d
Best 7 Coffee Makers (2025): Drip Is Drippin'

The old-fashioned drip coffee maker has come a long way. Our favorite machines here can turn your barista into a stranger.
Wired - 3d
Death of a Unicorn review – goofy eat-the-rich satire isn’t fun enough

SXSW film festival: Jenna Ortega, Paul Rudd and Richard E Grant lead a wasted cast in this silly and exasperating mishmash of comedy and gore. The unicorn has been a staple of folk mythology for ...
The Guardian - 1d
The M3 iPad Air Is Unsurprisingly Good

The iPad Air with M3 isn’t much different, but that shouldn’t surprise you.
Inc. - 4h
Hikma races to launch generic versions of blockbuster obesity drugs

Pharma group looks to take advantage as Wegovy and Ozempic start to go off patent next year
Financial Times - 1d
More couples are choosing lab-grown diamonds over natural stones for engagement rings. Here’s why

Lab-grown diamonds outpace natural stones when it comes to engagement rings. Here’s why, and what to consider when shopping.
CNBC - 5h

More from MarketWatch

Trump’s first 50 days: Stocks heading toward worst start to a presidential term since 2009

The first 50 days of President Donald Trump’s second term have brought heightened volatility to financial markets already worried about slowing economic growth in the world’s largest economy.
MarketWatch - 17m
Tesla’s stock has lost its ‘Trump bump.’ Here’s the latest bad news.

Tesla’s stock is sinking after another month of bad China sales. Elon Musk has now lost about $7 billion in his stake since the election.
MarketWatch - 20m
I viewed a $600K house, but discovered the kitchen extension has no foundation. Do I have a moral obligation to tell the seller’s agent?

“There was a bidding war.”
MarketWatch - 46m
Why are eggs so important in our battle against inflation?

Egg prices have become a symbol of our economic anxiety.
MarketWatch - 59m
Super Micro’s stock has its doubters, but it just got a vote of confidence

Super Micro is a “show-me story,” says a Rosenblatt analyst, but he sees room for gross margins to expand as the company sells more to enterprise customers.
MarketWatch - 1h

More in Business

Elon Musk’s X suffers multiple outages

Elon Musk's social media platform X experienced several outages on Monday morning.
CNBC - 13m
Oil tanker hit by container ship in North Sea

Blaze rips through both vessels as UK emergency services rescue 37 crew members
Financial Times - 15m
Trump’s first 50 days: Stocks heading toward worst start to a presidential term since 2009

The first 50 days of President Donald Trump’s second term have brought heightened volatility to financial markets already worried about slowing economic growth in the world’s largest economy.
MarketWatch - 17m
Rules for repaying Social Security benefits are about to get stricter. Here's what to know

Social Security beneficiaries who receive more money than they are owed will now face a 100% default withholding rate from their monthly checks, the agency said.
CNBC - 18m
Tesla’s stock has lost its ‘Trump bump.’ Here’s the latest bad news.

Tesla’s stock is sinking after another month of bad China sales. Elon Musk has now lost about $7 billion in his stake since the election.
MarketWatch - 20m